search icon
  • Print
  • ShareThis
  • Text Size
  • IDSA, HIVMA & PIDS Statement on Express Scripts Partnership with Imprimis


    IDSA, HIVMA and PIDS applaud the news that Express Scripts is taking steps to improve access to obtaining pyrimethamine for patients with toxoplasmosis. We urge other private and public health insurers and pharmacy benefits managers to also make this option available to their beneficiaries.
    Since the price increase taken by Turing Pharmaceuticals in August, our infectious diseases and HIV medical provider members have reported significant challenges obtaining pyrimethamine for their patients. Turing’s announcement last week that they do not intend to lower the drug’s list price heightens the need to identify new options for medical providers and their patients. We are optimistic that this arrangement will help address the serious cost and access barriers that have prevented or delayed pregnant women, infants, and patients with HIV infection or following transplantation from accessing this lifesaving treatment.
    IDSA and HIVMA stand ready to educate our membership of more than 10,000 infectious diseases and HIV medical providers on this new option for obtaining pyrimethamine for their patients being treated for toxoplasmosis – whether the treatment is being given in or outside of the hospital.
    Toxoplasmosis is a parasitic infection that mainly affects patients with compromised immune systems, such as patients infected with HIV, those undergoing cancer therapy or following transplantation, and pregnant women and their newborns, because their immune system is unable to control their infection. If not effectively treated, severe toxoplasmosis can cause brain and organ damage and result in blindness or death. Patients with HIV infection and other immunocompromising conditions require a minimum of eight months of treatment with many patients requiring a year or more.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site